회사 개요
Kiniksa Pharmaceuticals International, plc operates within the healthcare sector as a biopharmaceutical entity focused on developing and commercializing specialized medical therapies across the United States, the United Kingdom, and international markets. Its core business activity involves the commercialization of specific drug candidates, most notably ARCALYST, which functions as an interleukin-1alpha and 1beta cytokine trap designed for the treatment of recurrent pericarditis. The company's current market capitalization stands at $3.62B, while its trailing twelve-month revenue totals $677.56M, supported by an operational workforce of 366 employees. These valuation and revenue figures position the firm as a mid-to-large-cap specialty drug manufacturer with a significant asset base relative to its peer group in the specialty and generic drug industry.
재무 건전성
The company reported annual revenue of $677.56M, net income of $59.01M, and EBITDA of $78.78M for the trailing twelve-month period, indicating a robust operational cash generation capability before interest and tax obligations. The disparity between the $677.56M revenue and the $59.01M net income reveals a cost structure where operating expenses and taxes consume approximately 91.3% of gross sales, a typical profile for pharmaceutical firms facing high R&D and commercialization costs. Free cash flow reached $97.89M, demonstrating that the company generates substantial liquidity after capital expenditures, which provides significant financial flexibility for reinvestment in pipeline assets or strategic acquisitions. Profitability metrics further delineate the financial efficiency, with a gross margin of 54.7% reflecting the high value of specialty drug sales, an operating margin of 9.8% showing moderate efficiency in controlling overhead, and a profit margin of 8.7% confirming the final return on sales after all expenses. Liquidity and leverage analysis shows the company holds $414.07M in cash against only $9.50M in debt, resulting in a conservative balance sheet profile. This position is reinforced by a debt-to-equity ratio of 1.67, which, while non-zero, is manageable given the deep cash reserves, and a current ratio of 3.79, which indicates strong short-term liquidity sufficient to cover current liabilities multiple times over. Return metrics highlight management effectiveness, with a return on equity of 11.7% and a return on assets of 7.2%, suggesting that the company is generating solid returns on the shareholders' capital and the total asset base employed.
밸류에이션 평가
Valuation multiples indicate the market's pricing expectations, with a trailing P/E ratio of 63.11 and a forward P/E of 29.18, implying that the market anticipates a substantial reduction in earnings per share over the coming year or that current earnings are being re-rated. The significant compression between the trailing and forward P/E suggests the market expects a sharp increase in earnings growth or a reclassification of the company's earnings quality. The price-to-book ratio of 6.36 indicates that the stock trades at a substantial premium over its book value, reflecting investor confidence in the intangible assets and future cash flow potential of the biopharmaceutical pipeline rather than just tangible assets. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 5.35 and an EV/EBITDA of 40.85, suggesting the company is valued heavily on its sales volume and pre-tax cash generation rather than current profitability levels. Price momentum data shows a 52-week high of $50.03 and a 52-week low of $18.25, placing the current trading range within a wide historical band that highlights the asset's recent volatility. The beta of 0.06 indicates that the stock price exhibits extremely low volatility relative to the broader market, moving independently of general market indices, which is common for small-cap biotech stocks with idiosyncratic growth drivers.
Growth & Income
Revenue growth for the trailing twelve-month period reached an impressive 65.0% year-over-year, signaling aggressive top-line expansion likely driven by market access or product uptake in recurrent pericarditis. Earnings growth data is listed as N/A, which implies that while revenue is expanding rapidly, the calculation for earnings growth may be constrained by non-recurring items or specific accounting adjustments that prevent a standard year-over-year comparison. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of retaining all net income to fund research and development activities rather than distributing cash to shareholders. This reinvestment approach is typical for biopharmaceutical companies in the growth phase, where capital allocation prioritizes expanding the therapeutic portfolio over immediate income generation for investors. The overall growth and income profile reflects a high-growth, zero-dividend trajectory where shareholder value is expected to accrue through potential stock appreciation and future product approvals rather than current income distributions.